CJC-1295 references

Detection and sporting rules

The antibody-free assay sits beside the GHRH-analog detection review, the 2-10 kDa doping-control methods paper and the identification of an unknown preparation. I value the exactness of this work: it asks whether an analytical method can find or identify a substance.

The WADA Prohibited List supplies the sporting rule. Reading it alongside the assays makes the eligibility question clearer; athletic efficacy still requires different evidence.

Human and animal work

The Teichman healthy-adult study, Ionescu and Frohman pulsatility paper and Sackmann-Sala serum-protein study cover the central human findings. The Jette rat study and Alba GHRH-knockout mouse study address different experimental settings.

Clinical and safety context

The reviews of GHRH pharmacology and analog development, the tesamorelin outcomes analysis and the musculoskeletal peptide safety review give the clinical context. The IGF-1 cancer-risk meta-analysis, GH sodium-retention study and GHRH-analog insulin-sensitivity study inform the safety questions.

The FDA briefing materials, discontinued trial registry and the Modified GRF reference complete the list. I would read an uncertain clinical claim back to the experiment that supposedly supports it; the full bibliography follows.